Over the coming days, Philips will be presenting its latest solutions in cardiology and new late-breaking clinical data at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting (October 23-26 in San Francisco, USA). Philips will feature a comprehensive portfolio of image-guided therapy and echocardiography solutions that integrate advanced imaging systems and software with specialized diagnostic and therapeutic devices, creating a holistic approach to support high-quality treatment, even for complex medical procedures. The company will also share clinical data and cutting-edge research from a five-year study comparing patient outcomes in the diagnosis and treatment of heart disease using instant wave-free ratio (iFR) and fractional flow reserve (FFR).
At TCT, the Philips Engagement Hub, located in the exhibit hall at the Moscone Center, will offer a well-rounded variety of activities, including physician-led discussions, in-depth symposia, and hands-on training sessions. These events are designed to address a range of key challenges in the field of cardiology, providing valuable opportunities for knowledge exchange and professional development.
“As a leader in cardiology innovation, Philips is uniquely positioned to deliver solutions that integrate imaging, devices, software, informatics and services at each point of a heart patient’s journey,” said Bert van Meurs, Chief Business Leader, Image Guided Therapy and Precision Diagnosis. “By collaborating with our customers to bring purposeful innovation to cardiology and beyond, we further validate our advanced technologies and the clinical and economic evidence supporting them – all to improve patient care more efficiently.”
The company’s latest technology advancements in diagnostic, interventional and monitoring solutions featured at TCT 2023 include: